

## **MicroPhage, Inc. Announces the Formation of Its Medical Advisory Board**

**Longmont, CO** - May 11, 2011 – MicroPhage Inc. announced today that it has formed a Medical Advisory Board to guide the Company as it moves into the commercialization phase of its novel diagnostic technology. The board is comprised of four internationally recognized clinicians in the field of pathogenic bacteria and antibiotic susceptibility. Richard Proctor, M.D., will chair the committee.

*“The creation of a strong, influential Medical Advisory Board highlights our commitment to the advancement of our clinical diagnostic platform,”* said Donald Mooney, President and Chief Executive Officer of MicroPhage. *“We are encouraged by our clinical trial performance and recognize the immense potential of our technology. The Medical Advisory Board will play a critical role in guiding our application of this technology to maximize benefit to the healthcare community.”*

The members Medical Advisory Board include:

### **Richard A. Proctor, M.D.**

Professor Emeritus, Medical Microbiology and Immunology  
Professor Emeritus, Department of Medicine  
University of Wisconsin  
School of Medicine and Public Health  
Madison, Wisconsin

### **Dr. Henry Chambers, M.D.**

San Francisco General Hospital/UCSF  
Professor of Medicine  
Chief, Division of Infectious Diseases, SFGH

### **Dr. Joseph Guglielmo, Pharm.D.**

University of San Francisco Medical Center  
Chair, Department of Clinical Pharmacy  
Professor of Clinical Pharmacy  
Thomas A. Oliver Chair in Clinical Pharmacy

### **Dr. Jack Brown, Pharm.D., MS.**

Clinical Assistant Professor  
School of Pharmacy and Pharmaceutical Services  
State University of New York  
University at Buffalo

### **About MicroPhage**

Based in Longmont, Colorado, privately held MicroPhage, Inc. develops accelerated, easy-to-use diagnostic products for bacterial identification and antibiotic susceptibility/resistance testing. Using its proprietary Bacteriophage Amplification Test (BAT™) platform, the Company has developed patented processes that provide a platform for quick, easy-to-use, inexpensive diagnostic tests. The MicroPhage BATTM test platform does not require any instrumentation and is simple to operate, enabling microbiology testing outside of traditional laboratory settings.

### **For further information please contact:**

Brian MacDonald, VP Marketing & Sales, MicroPhage, Inc., 1-855-KeyPath (539-7284)